HomeNewsCrams business

Crams Business

Jump to

Why PI Industries is a preferred pick in the agrochemical space

The acquisitions in the pharma API and intermediates business will be earnings and value-accretive.
Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

Arpit Vyas, MD of Dishman Pharma presents his views on the company‘s quarterly earnings, in an interview to CNBC-TV18.
Parabolic Drugs set to launch 17 products in 3 yrs

Vineet Gupta, director of Parabolic Drugs spoke to CNBC-TV18 about the latest with is company and the way ahead.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Crams Business

Why PI Industries is a preferred pick in the agrochemical space

Dishman Pharma post standalone Q2 PAT at Rs 13.52cr sans Fx

Parabolic Drugs set to launch 17 products in 3 yrs